| 魏莉娜,王月平,朱秋霞,任星星,贾利清.左西孟旦联合沙库巴曲缬沙坦钠对慢性心衰患者血流动力学和运动能力的影响[J].现代生物医学进展英文版,2020,(22):4315-4318. |
| 左西孟旦联合沙库巴曲缬沙坦钠对慢性心衰患者血流动力学和运动能力的影响 |
| Effects of Levosimendan Combined with Sacubitril Valsartan on Hemodynamics and Exercise Capacity in Patients with Chronic Heart Failure |
| Received:February 28, 2020 Revised:March 23, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.22.025 |
| 中文关键词: 左西孟旦 沙库巴曲缬沙坦钠 慢性心衰 血流动力学 运动能力 |
| 英文关键词: Levosimendan Sacubitril Valsartan Chronic heart failure Hemodynamics Exercise capacity |
| 基金项目:内蒙古自治区自然科学基金项目（2018MS08130） |
|
| Hits: 728 |
| Download times: 566 |
| 中文摘要: |
| 摘要 目的：探讨左西孟旦联合沙库巴曲缬沙坦钠（诺欣妥）对慢性心衰患者血流动力学和运动能力的影响。方法：2018年1月至2019年5月选择在本院心内科诊治的慢性心衰患者80例，根据随机数字表法分为联合组50例，对照组30例。两组入院后均进行常规治疗，在此基础上，对照组给予沙库巴曲缬沙坦钠治疗，联合组给予沙库巴曲缬沙坦钠联合左西孟旦治疗，两组都治疗观察1个月，记录血流动力学和运动能力的变化情况。结果：治疗后联合组的总有效率显著高于对照组(98.0 % vs 80.0 %，P<0.05)。治疗后联合组的总有效率显著高于对照组(98.0 % vs 80.0 %，P<0.05)。两组治疗前(left ventricular ejection fraction，LVEF)值和(Left ventricular end-systolic diameter，LVSD)值比较无统计学意义(P>0.05)，治疗1个月后，两组的的LVEF值显著高于治疗前，LVSD值显著低于治疗前(P<0.05)，且上述指标的变化联合组更为显著(P<0.05)。两组治疗后的6 min步行距离都显著高于治疗前(P<0.05)，且联合组也显著高于对照组(P<0.05)。结论：左西孟旦联合沙库巴曲缬沙坦钠治疗慢性心衰能改善患者的血流动力学状况和运动能力，从而提高治疗疗效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Levosimendan combined with Sacubitril Valsartan on hemodynamics and exercise capacity in chronic heart failure patients. Methods: From January 2018 to May 2019, 80 patients with chronic heart failure who were diagnosed and treated in in the Department of Cardiology of our hospital were enrolled and were divided into the combination group (50 cases) and the control group (30 cases) accorded to the random number table method. After the two groups were admitted routine treatment, on the basis of this, the control group was treated with Sacubitril Valsartan, the combination group was treated with Levosimendan combined with Sacubitril Valsartan. The two groups were treated for 1 month, and the changes of hemodynamics and exercise capacity were recorded. Results: The total effective rate of the combination group after treatment was significantly higher than that of the control group (98.0% vs 80.0%, P<0.05). There were no significant differences in the values of left ventricular ejection fraction (LVEF) and (Left ventricular end-systolic diameter, LVSD) between the two groups (P>0.05). After 1 month of treatment, the LVEF values of the two groups after treatment were significantly higher, and the LVSD values were significantly lower (P<0.05), and the change of the above indicators was more significant in the combination group (P<0.05). The 6-minute walking distance after treatment were significantly higher than that before treatment (P<0.05), and the combination group were also significantly higher than the control group (P<0.05). Conclusion: Levosimendan combined with Sacubitril Valsartan in the treatment of chronic heart failure can improve the hemodynamics and exercise capacity of patients, and thus improve the therapeutic effect. |
|
View Full Text
View/Add Comment Download reader |
| Close |
